AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 10732745
Drug: Three cycles
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three cycles of FEC followed by high-dose chemotherapy with alkylating agents (CTCb)
Trial: 10732745
Drug: Six cycles
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Six cycles of standard intravenous CMF (cyclophosphamide, methotrexate, and fluorouracil)
Trial: 9004446
Drug: Three dose
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three dose pre-exposure series (days 0, 7, and 28) followed by one booster dose (day 360)
Trial: 9004446
Drug: Five dose
RxNorm normalized name: fivehorn smotherweed pollen extract
DrugBank: Bassia hyssopifolia pollen (DB10941)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Five dose simulated post-exposure series (days 0, 3, 7, 14, and 28)
Trial: 9004446
Drug: Lyssavac‐HDC vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lyssavac‐HDC vaccine
Trial: 1547049
Drug: metoprolol 1
RxNorm normalized name: metoprolol 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: metoprolol 1 mg
Trial: 1547049
Drug: propranolol 1
RxNorm normalized name: propranolol 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: propranolol 1 mg
Trial: 29235162
Drug: Silymarin (140
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silymarin (140 mg, thrice daily for 12 weeks)
Trial: 26928828
Drug: Patients feeling
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients feeling relatively healthy by the second day of treatment
Trial: 17437727
Drug: Baseline platelet
RxNorm normalized name: platelet glycoprotein VI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline platelet count >= 234 x 10(9)/L
Trial: 17437727
Drug: Baseline platelet
RxNorm normalized name: platelet glycoprotein VI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline platelet count < 234 x 10(9)/L
Trial: 15126550
Drug: 1000 mg
RxNorm normalized name: bran 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg Testosterone Undecanoate (TU)
Trial: 15126550
Drug: 1000 mg
RxNorm normalized name: bran 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg Testosterone Undecanoate (TU) plus 150 mg Depot Medroxyprogesterone Acetate (DMPA)
Trial: 15126550
Drug: 1000 mg
RxNorm normalized name: bran 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg Testosterone Undecanoate (TU) plus 300 mg Depot Medroxyprogesterone Acetate (DMPA)
Trial: 9458602
Drug: Bass appliance
RxNorm normalized name: Largemouth bass
DrugBank: Largemouth bass (DB10976)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bass appliance treatment for 6 months
Trial: 7962682
Drug: Transdermal nicotine
RxNorm normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal nicotine (7 mg)
Trial: 7962682
Drug: Transdermal nicotine
RxNorm normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal nicotine (14 mg)
Trial: 7962682
Drug: Recovery night
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recovery night after active nicotine patch
Trial: 3619425
Drug: Cefoperazone 1
RxNorm normalized name: cefoperazone 100 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefoperazone 1 g
Trial: 3619425
Drug: Cefoperazone 2
RxNorm normalized name: cefoperazone 20 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefoperazone 2 g
Trial: 31742615
Drug: High-Dose Vitamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-Dose Vitamin D Supplementation (10,000 IU)
Trial: 31742615
Drug: Low-Dose Vitamin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-Dose Vitamin D Supplementation (400 IU)
Trial: 28960888
Drug: Naldemedine (0.1-100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naldemedine (0.1-100 mg)
Trial: 28960888
Drug: Naldemedine (3-30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naldemedine (3-30 mg once daily for 10 days)
Trial: 31753009
Drug: 6 mg
RxNorm normalized name: boron 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg nicotine gum
Trial: 26537155
Drug: 75 mg
RxNorm normalized name: talc 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg moclobemide
Trial: 26537155
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 6 mg nicotine gum and 75 mg moclobemide
Trial: 22914208
Drug: 0.005% estriol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.005% estriol vaginal gel (50 μg per application, 1 g daily for 3 weeks, then twice weekly up to 12 weeks)
Trial: 17395395
Drug: Olanzapine (OLA)
RxNorm normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Olanzapine (OLA) 2.5 mg for 1 month and 5 mg for 2 months
Trial: 16359548
Drug: Efalizumab 1
RxNorm normalized name: efalizumab 100 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Efalizumab 1 mg/kg/wk
Trial: 15761420
Drug: Efalizumab 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Efalizumab 2 mg/kg/wk
Trial: 15761420
Drug: Efalizumab (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Efalizumab (1 or 2 mg/kg)
Trial: 6287838
Drug: Wheat bran
RxNorm normalized name: Wheat bran
DrugBank: Wheat bran (DB10685)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wheat bran (20 g/day)
Trial: 6287838
Drug: Corn bran
RxNorm normalized name: CORN BRAN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corn bran (20 g/day)
Trial: 28345425
Drug: 1% diclofenac/3%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% diclofenac/3% menthol gel (n=117)
Trial: 9324620
Drug: Intrafusin 10%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrafusin 10% (10 ml/kg BW/24 h of 10% amino acid solution)
Trial: 9324620
Drug: Aminosteril 10%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aminosteril 10% (10 ml/kg BW/24 h of 10% amino acid solution)
Trial: 9324620
Drug: Isotonic electrolyte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isotonic electrolyte solution (Jonosteril, control group) (10 ml/kg BW/24 h)
Trial: 7968327
Drug: Desmopressin acetate
RxNorm normalized name: Desmopressin Acetate
DrugBank: Desmopressin (DB00035)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Desmopressin acetate (0.3 microgram/kg intravenous infusion one hour after cardiopulmonary bypass)
Trial: 3884697
Drug: Metoclopramide 10
RxNorm normalized name: metoclopramide 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide 10 mg parenterally
Trial: 3884697
Drug: Metoclopramide 10
RxNorm normalized name: metoclopramide 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide 10 mg orally
Trial: 3371390
Drug: Metoprolol CR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol CR 100 mg
Trial: 3371390
Drug: Metoprolol CR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol CR 200 mg
Trial: 15909439
Drug: Topical negative
RxNorm normalized name: GLYCERIN NEGATIVE CONTROL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical negative pressure (TNP)
Trial: 12945135
Drug: Laser radiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laser radiation treatment
Trial: 19886855
Drug: Irbesartan 150
RxNorm normalized name: irbesartan 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irbesartan 150 mg to 300 mg
Trial: 10862446
Drug: Enalapril 10
RxNorm normalized name: enalapril 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril 10 mg to 20 mg
Trial: 3709379
Drug: Caloric restricted
RxNorm normalized name: Chloric acid
DrugBank: Chloric acid (DB14150)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caloric restricted diet (300 kcal/d) over 4 weeks + ergometer exercise programme (up to 2 hours daily)
Trial: 18334500
Drug: Multiple regression
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple regression model including treatment and covariates
Trial: 18334500
Drug: Ecologic approach
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ecologic approach using grouped treatment variable
Trial: 14524508
Drug: Comparison group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison group (no NMES treatment)
Trial: 9352394
Drug: 0, 12.5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0, 12.5, 25, 50, and 100 mg triamterene
Trial: 9352394
Drug: 0, 25,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0, 25, and 50 mg triamterene with 12.5 and 25 mg hydrochlorothiazide
Trial: 3940620
Drug: Trioxifene mesylate
RxNorm normalized name: mesylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trioxifene mesylate (5 mg, 10 mg, 20 mg orally twice daily)
Trial: 3940620
Drug: Tamoxifen (previous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen (previous treatment)
Trial: 30046738
Drug: Dabigatran etexilate
RxNorm normalized name: Dabigatran etexilate
DrugBank: Dabigatran etexilate (DB06695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dabigatran etexilate (DE) administered twice daily for 3 months
Trial: 30046738
Drug: Standard of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care (SOC) including unfractionated heparin (UFH) or low‐molecular‐weight heparin (LMWH) for 3 months
Trial: 12547742
Drug: Glucosamine (2,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucosamine (2,000 mg per day for 12 weeks)
Trial: 8740466
Drug: Experimental hostility-reduction
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental hostility-reduction treatment group
Trial: 7072622
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g beta‐sitosterol
Trial: 7072622
Drug: 2 g
RxNorm normalized name: Molds 2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g beta‐sitosteryl oleate
Trial: 26511218
Drug: Postoperative low-level
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative low-level laser therapy (LLLT) treatment for 21 days
Trial: 26511218
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group without postoperative laser treatment
Trial: 23169523
Drug: Parenteral hydration
RxNorm normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral hydration (normal saline 1 L per day)
Trial: 23169523
Drug: Placebo (normal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (normal saline 100 mL per day)
Trial: 21114535
Drug: YSPSL (recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: YSPSL (recombinant P-selectin glycoprotein ligand Ig) administered systemically to the recipient pre-reperfusion.
Trial: 21114535
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no YSPSL treatment).
Trial: 20133269
Drug: Initial antiretroviral
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Initial antiretroviral therapy with resistance mutations at baseline
Trial: 20133269
Drug: Initial antiretroviral
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Initial antiretroviral therapy without resistance mutations at baseline
Trial: 15559222
Drug: Cerebrolysin 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cerebrolysin 10 ml/d
Trial: 15559222
Drug: Cerebrolysin 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cerebrolysin 50 ml/d
Trial: 7566576
Drug: Perindopril (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perindopril (2 mg/day per os)
Trial: 2132299
Drug: Keto acids
RxNorm normalized name: Keto-C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Keto acids treatment for 12 months
Trial: 377154
Drug: Ibuprofen 400mg
RxNorm normalized name: IBUPROFEN 400MG TAB
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen 400mg t.d.s.
Trial: 30630671
Drug: 62.5 mg
RxNorm normalized name: quinine 162.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 62.5 mg acetazolamide twice daily
Trial: 30630671
Drug: 125 mg
RxNorm normalized name: niacin 125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 125 mg acetazolamide twice daily
Trial: 28072446
Drug: Dexamethasone 8
RxNorm normalized name: dexamethasone 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone 8 mg administered intravenously 30 minutes before surgery
Trial: 20704622
Drug: Rituximab (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rituximab (1000 mg courses, two doses with a 15-day interval)
Trial: 20704622
Drug: Cytotoxic combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cytotoxic combination therapy (pulse cyclophosphamide 1000 mg/monthly, azathioprine 2-3 mg/kg per day, and prednisolone 0.5 mg/kg per day)
Trial: 20704622
Drug: Cytotoxic combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cytotoxic combination therapy
Trial: 16295703
Drug: Quit and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quit and Win contest (30-day quit period, provider advice via weekly mailings, online and telephone quit assistance, media campaign, community support)
Trial: 9255754
Drug: Tibolone 2.5
RxNorm normalized name: tibolone 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tibolone 2.5 mg daily for 1 year
Trial: 3830248
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg indomethacin suppository administered at 9.00 hours
Trial: 3830248
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg indomethacin suppository administered at 21.00 hours
Trial: 30209962
Drug: Lidocaine (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine (1.5 mg/kg/h)
Trial: 30209962
Drug: Control (Continuous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (Continuous propofol infusion and fentanyl boluses)
Trial: 30209962
Drug: Dexmedetomidine (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (0.5 µg/kg/h)
Trial: 27428384
Drug: Soap and
RxNorm normalized name: Green soap and industrial methylated spirit only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soap and water bathing daily
Trial: 16206355
Drug: Milnacipran twice
RxNorm normalized name: MILNACIPRAN
DrugBank: Milnacipran (DB04896)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Milnacipran twice daily
Trial: 16206355
Drug: Milnacipran once
RxNorm normalized name: MILNACIPRAN
DrugBank: Milnacipran (DB04896)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Milnacipran once daily
Trial: 7575711
Drug: CAMPATH-1H (C1H)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAMPATH-1H (C1H) 0.3 mg/day
Trial: 7575711
Drug: CAMPATH-1H (C1H)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAMPATH-1H (C1H) 1.0 mg/day
Trial: 7575711
Drug: CAMPATH-1H (C1H)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAMPATH-1H (C1H) 3.0 mg/day
Trial: 7575711
Drug: CAMPATH-1H (C1H)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAMPATH-1H (C1H) 10.0 mg/day
Trial: 7575711
Drug: CAMPATH-1H (C1H)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAMPATH-1H (C1H) 30.0 mg/day
Trial: 26749079
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg intravitreal ranibizumab for three to 14 days before Ahmed glaucoma valve implantation
Trial: 23139071
Drug: Adjunctive photodynamic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjunctive photodynamic therapy using LED light (Fotosan) with toluidine blue O solution
Trial: 15134608
Drug: Extracorporeal shock
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Extracorporeal shock wave therapy (ESWT) using the Dornier Epos Ultra, single therapy session
Trial: 15134608
Drug: Sham treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham treatment (Control Group)
Trial: 8083130
Drug: Preoperative radiotherapy
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative radiotherapy (7 Gy single fraction administered < 4 h before surgery)
Trial: 8083130
Drug: Postoperative radiotherapy
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postoperative radiotherapy (5 fractions of 3.5 Gy, total dose 17.5 Gy administered < 72 h after surgery)
Trial: 8452170
Drug: Fleroxacin 400
RxNorm normalized name: fleroxacin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fleroxacin 400 mg once daily for 7 days
Trial: 2511802
Drug: Fleroxacin (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fleroxacin (600 or 800 mg) once daily for 7 days
Trial: 765518
Drug: Trimethoprim-sulfamethoxazole (trimethoprim,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimethoprim-sulfamethoxazole (trimethoprim, 10 mg; sulfamethoxazole, 50 mg/kg/day in divided doses every 12 hours)
Trial: 765518
Drug: Ampicillin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ampicillin (100 mg/kg/day administered in divided doses every six hours)
Trial: 24528807
Drug: Lipid-based nutrient
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipid-based nutrient supplement (LNS) 220kcal
Trial: 19541503
Drug: No supplements
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No supplements (control)
Trial: 22845008
Drug: BAF312 dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BAF312 dose titration regimen DT1 (0.25-10 mg over 9-10 days)
Trial: 22845008
Drug: BAF312 dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BAF312 dose titration regimen DT2 (0.25-10 mg over 9-10 days)
Trial: 22845008
Drug: BAF312 non-titration
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BAF312 non-titration regimen (10 mg starting dose)
Trial: 20975325
Drug: Cognitive-behavioral group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral group therapy (CBT-G)
Trial: 20975325
Drug: Preferred treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preferred treatment (either Sertraline or CBT-G)
Trial: 12888778
Drug: ketamine 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ketamine 0.1 mg/kg
Trial: 8967639
Drug: Anti-HAV (IgG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-HAV (IgG antibodies against hepatitis A virus)
Trial: 8967639
Drug: Anti-HBc (antibodies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-HBc (antibodies against hepatitis B virus core antigen)
Trial: 8967639
Drug: Anti-HCV (antibodies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-HCV (antibodies against hepatitis C virus)
Trial: 8967639
Drug: Anti-HEV (antibodies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-HEV (antibodies against hepatitis E virus)
Trial: 2932814
Drug: Bronchodilator (salbutamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bronchodilator (salbutamol 5 mg)
Trial: 2932814
Drug: Bronchodilator (ipratropium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bronchodilator (ipratropium 1 mg)
Trial: 26918314
Drug: Orthodontic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orthodontic treatment for Class I malocclusions
Trial: 24934787
Drug: Single-agent paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Single-agent paclitaxel (T)
Trial: 18512312
Drug: L‐asparaginase (6000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L‐asparaginase (6000 IU/m2, three times a week for 2 weeks) in VDLP regimen
Trial: 10343464
Drug: Self-administered PASI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-administered PASI (SAPASI)
Trial: 25899896
Drug: Ginger (2-g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginger (2-g ginger rhizomes powder as two 1-g tablets per day)
Trial: 21215809
Drug: Intravenous busulfan
RxNorm normalized name: Busulfan
DrugBank: Busulfan (DB01008)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous busulfan (3.2 mg/kg/day)
Trial: 15504987
Drug: Intranasal insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal insulin (4 x 40 IU/day)
Trial: 3315535
Drug: Esaprazole 900
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esaprazole 900 mg/day
Trial: 3315535
Drug: Esaprazole 1350
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esaprazole 1350 mg/day
Trial: 28902035
Drug: Small-particle hyaluronic
RxNorm normalized name: Smallanthus sonchifolius whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Small-particle hyaluronic acid (SPHA) injectable gel
Trial: 15156935
Drug: Cranberry extract
RxNorm normalized name: CRANBERRY EXTRACT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cranberry extract (2 g daily for 6 months)
Trial: 23276892
Drug: Preoperative PTCD
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative PTCD with bile re‐infusion (n = 56)
Trial: 23276892
Drug: Conservative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative treatment alone (n = 60)